Corteva
CTVA
$82.95
-0.67%
Corteva, Inc. is a global leader in the agricultural inputs industry, specializing in the development and sale of seed and crop protection products. The company operates as a pure-play entity following its 2019 spin-off from DowDuPont, with its Seeds segment historically generating the majority of profits. The current investor narrative is dominated by the company's planned strategic transformation, specifically its intention to spin off its seeds business in late 2026, which would reposition Corteva as a pure-play crop protection company, creating significant debate around the future value and focus of the separate entities.…
CTVA
Corteva
$82.95
CTVA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $107.84 and implied upside of +30.0% versus the current price.
Average Target
$107.84
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$66 - $108
Analyst target range
Analyst coverage for CTVA is limited, with only 5 analysts providing estimates, which is typical for a company of its size and profile following a recent spin-off. The consensus leans bullish, with recent institutional ratings including actions like 'Outperform' from Mizuho and 'Overweight' from Wells Fargo, though JP Morgan downgraded from 'Overweight' to 'Neutral' in early February 2026. The average revenue estimate for the next period is $19.29 billion, with a range from $18.93 billion to $19.69 billion, indicating a relatively tight spread and moderate growth expectations. The target price range is not provided in the data, so the implied upside or downside cannot be calculated. The limited coverage and lack of a published target price range can lead to higher volatility and less efficient price discovery, as the stock is less scrutinized by the broader institutional investment community.
Bulls vs Bears: CTVA Investment Factors
The bull case is primarily driven by powerful technical momentum, a fortress balance sheet, and strong cash generation, which provide a defensive foundation during a major corporate transformation. The bear case centers on the severe cyclicality of earnings, weak recent revenue trends, and the high execution risk of the upcoming spin-off. Currently, the bullish evidence appears stronger, supported by the stock's persistent uptrend and solid financials. However, the single most important tension in the investment debate is whether the company's robust free cash flow and low volatility can outweigh the extreme earnings volatility and successfully navigate the value-unlocking but risky seed business separation. The resolution of this spin-off's execution and market reception will be the primary determinant of future stock performance.
Bullish
- Strong Technical Uptrend: The stock has gained 44.68% over the past year and 22.11% over the last three months, significantly outperforming the SPY. It is trading at 98% of its 52-week high ($85.63), indicating persistent buying pressure and strong momentum.
- Robust Free Cash Flow Generation: The company generated $2.82 billion in free cash flow over the trailing twelve months. This provides significant financial flexibility to fund operations, shareholder returns, and strategic initiatives ahead of the planned seed business spin-off.
- Solid Balance Sheet with Low Debt: Corteva maintains a strong current ratio of 1.43 and an exceptionally low debt-to-equity ratio of 0.11. This conservative financial structure reduces risk and provides a stable foundation for the upcoming corporate transformation.
- Valuation De-rating from Historical Highs: The current Price-to-Sales ratio of 2.59x is significantly below the 11.54x recorded at the end of Q4 2025. This compression suggests much of the uncertainty around the spin-off and cyclical earnings may already be priced in, offering a more attractive entry point.
Bearish
- Severe Cyclical Profitability Volatility: Q4 2025 results showed a net loss of $552 million and a gross margin of 38.29%, a sharp decline from Q2 2025's net income of $1.31 billion and 54.58% margin. This extreme seasonality and input-cost sensitivity create significant earnings uncertainty.
- Weak Recent Revenue Growth: Q4 2025 revenue of $3.91 billion declined 1.71% year-over-year. This follows a volatile quarterly pattern, indicating inconsistent top-line performance and potential challenges in driving consistent growth.
- High Valuation on Forward Earnings: The forward P/E ratio of 20.70x is elevated, especially for a company with such volatile profitability. This high multiple requires a significant and sustained earnings recovery to justify, which is not guaranteed given the cyclical nature of the business.
- Limited Analyst Coverage & Price Discovery: Only 5 analysts cover the stock, and no target price range is provided. This limited scrutiny can lead to higher volatility and less efficient price discovery, increasing investment risk.
CTVA Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 44.68% gain over the past year and a 22.11% rise over the last three months. As of the latest close at $83.83, the price is trading at approximately 98% of its 52-week high of $85.63, indicating it is near peak momentum levels and potentially susceptible to profit-taking or overextension. Recent momentum remains robust, with a 6.61% gain over the past month, which not only continues the longer-term uptrend but also significantly outperforms the broader market, as shown by a relative strength of +6.15% versus the SPY. This consistent upward trajectory across all measured timeframes suggests strong and persistent buying pressure. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $85.63 and support at the 52-week low of $57.00. A decisive breakout above $85.63 could signal a continuation of the bull run, while a failure could lead to a consolidation phase. The stock's beta of 0.68 indicates it is 32% less volatile than the broader market, which is a critical factor for risk management, suggesting it may offer a more defensive posture within a growth-oriented trend.
Beta
0.68
0.68x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$59-$86
Price range past year
Annual Return
+37.6%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | +4.7% | +4.9% |
| 3m | +18.6% | +0.6% |
| 6m | +36.0% | +5.1% |
| 1y | +37.6% | +28.8% |
| ytd | +22.4% | +1.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Revenue growth has been inconsistent, with the most recent Q4 2025 revenue of $3.91 billion representing a 1.71% year-over-year decline. This follows a volatile quarterly pattern, including strong growth in Q2 2025 ($6.46 billion, up from $6.11 billion YoY) and a sharp drop in Q3 2025 ($2.62 billion). Segment data shows Crop Protection revenue of $2.17 billion slightly outpacing Seed revenue of $1.74 billion in the latest period, highlighting the mixed performance across business lines. Profitability is highly cyclical and currently under pressure, with the company reporting a net loss of $552 million and a gross margin of 38.29% in Q4 2025. This contrasts sharply with a net income of $1.31 billion and a gross margin of 54.58% in Q2 2025, illustrating the seasonal and input-cost sensitive nature of the agricultural business. The balance sheet and cash flow position, however, appear solid. The company maintains a strong current ratio of 1.43 and a very low debt-to-equity ratio of 0.11. More importantly, it generated substantial free cash flow of $2.82 billion over the trailing twelve months, providing ample internal funding for operations, shareholder returns, and strategic initiatives ahead of the planned spin-off.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.38%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Given the company's inconsistent profitability, with a trailing twelve-month net income of $0.024 per share, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 2.59x and an Enterprise Value-to-Sales (EV/Sales) of 3.16x. The forward PE of 20.70x, based on estimated earnings, suggests the market anticipates a significant recovery in profitability. Compared to sector averages, data is not available for a direct industry multiple comparison. Historically, the current PS ratio of 2.59x sits well below its own historical range observed in recent quarters, such as the 11.54x recorded at the end of Q4 2025. This significant compression suggests the market has already de-rated the stock, potentially pricing in the uncertainty surrounding the seed business spin-off and cyclical earnings volatility, moving it away from peak valuation levels.
PE
41.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -239x~257x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by extreme earnings cyclicality. The company swung from a $1.31 billion net profit in Q2 2025 to a $552 million loss in Q4 2025, with gross margins collapsing from 54.58% to 38.29% in the same period. This volatility makes forecasting difficult and increases the risk of earnings misses. While free cash flow of $2.82 billion is strong, revenue growth is inconsistent, with a recent 1.71% YoY decline, indicating potential market share or pricing pressures. The low debt-to-equity of 0.11 mitigates financial risk but does not eliminate operational headwinds.
Market & Competitive Risks include valuation compression, as the forward P/E of 20.70x is high for a cyclical business and could contract if earnings recovery falters. The stock trades at 98% of its 52-week high, suggesting limited near-term upside and susceptibility to profit-taking. The planned spin-off introduces significant uncertainty; the market may struggle to value the separate crop protection and seed entities, potentially leading to a 'conglomerate discount' persisting or a failed value-creation event. The low beta of 0.68 offers defensive appeal but may limit upside in a raging bull market for the sector.
Worst-Case Scenario involves a perfect storm of cyclical downturn and spin-off mis-execution. A deeper-than-expected agricultural recession could push quarterly losses beyond recent levels, while complications in separating the seed business (regulatory, tax, operational) could destroy anticipated shareholder value. This could trigger multiple compression and a flight to safety. The realistic downside could see the stock re-test its 52-week low of $57.00, representing a potential loss of approximately -32% from the current price of $83.83. The historical max drawdown of -20.9% provides a benchmark, but a failed strategic pivot could drive losses beyond this level.